Literature DB >> 17314971

Melanoma biology and new targeted therapy.

Vanessa Gray-Schopfer1, Claudia Wellbrock, Richard Marais.   

Abstract

Melanoma is a cancer that arises from melanocytes, specialized pigmented cells that are found predominantly in the skin. The incidence of melanoma is rising steadily in western populations--the number of cases worldwide has doubled in the past 20 years. In its early stages malignant melanoma can be cured by surgical resection, but once it has progressed to the metastatic stage it is extremely difficult to treat and does not respond to current therapies. Recent discoveries in cell signalling have provided greater understanding of the biology that underlies melanoma, and these advances are being exploited to provide targeted drugs and new therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314971     DOI: 10.1038/nature05661

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  439 in total

1.  Selenium-containing histone deacetylase inhibitors for melanoma management.

Authors:  Raghavendra Gowda; Subbarao V Madhunapantula; Dhimant Desai; Shantu Amin; Gavin P Robertson
Journal:  Cancer Biol Ther       Date:  2012-06-06       Impact factor: 4.742

2.  Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.

Authors:  Anna E Vilgelm; Jeff S Pawlikowski; Yan Liu; Oriana E Hawkins; Tyler A Davis; Jessica Smith; Kevin P Weller; Linda W Horton; Colt M McClain; Gregory D Ayers; David C Turner; David C Essaka; Clinton F Stewart; Jeffrey A Sosman; Mark C Kelley; Jeffrey A Ecsedy; Jeffrey N Johnston; Ann Richmond
Journal:  Cancer Res       Date:  2014-11-14       Impact factor: 12.701

Review 3.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

4.  Cancer: A drug-resistant duo.

Authors:  Hugo Lavoie; Marc Therrien
Journal:  Nature       Date:  2011-12-14       Impact factor: 49.962

Review 5.  A brief history of melanoma: from mummies to mutations.

Authors:  Vito W Rebecca; Vernon K Sondak; Keiran S M Smalley
Journal:  Melanoma Res       Date:  2012-04       Impact factor: 3.599

6.  Emerging strategies for the identification and targeting of cancer stem cells.

Authors:  Jun Dou; Ning Gu
Journal:  Tumour Biol       Date:  2010-03-25

7.  Radiofluorinated rhenium cyclized α-MSH analogues for PET imaging of melanocortin receptor 1.

Authors:  Gang Ren; Shuanlong Liu; Hongguang Liu; Zheng Miao; Zhen Cheng
Journal:  Bioconjug Chem       Date:  2010-11-12       Impact factor: 4.774

Review 8.  Impact of the Protein Data Bank on antineoplastic approvals.

Authors:  John D Westbrook; Rose Soskind; Brian P Hudson; Stephen K Burley
Journal:  Drug Discov Today       Date:  2020-02-14       Impact factor: 7.851

Review 9.  Isolated limb infusion as a model to test new agents to treat metastatic melanoma.

Authors:  Michael E Lidsky; Paul J Speicher; Betty Jiang; Masahito Tsutsui; Douglas S Tyler
Journal:  J Surg Oncol       Date:  2013-11-20       Impact factor: 3.454

10.  Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation.

Authors:  Che-Hung Shen; Ping Yuan; Rolando Perez-Lorenzo; Yaqing Zhang; Sze Xian Lee; Yang Ou; John M Asara; Lewis C Cantley; Bin Zheng
Journal:  Mol Cell       Date:  2013-10-03       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.